Compare · AMED vs TOI
AMED vs TOI
Side-by-side comparison of Amedisys Inc (AMED) and The Oncology Institute Inc. (TOI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMED and TOI operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- AMED is the larger of the two at $4.20B, about 8.2x TOI ($512.9M).
- TOI has hit the wire 7 times in the past 4 weeks while AMED has been quiet.
- AMED has more recent analyst coverage (25 ratings vs 8 for TOI).
- Company
- Amedisys Inc
- The Oncology Institute Inc.
- Price
- $100.98-0.00%
- $5.12+5.13%
- Market cap
- $4.20B
- $512.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 25
- 8
Amedisys Inc
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
The Oncology Institute Inc.
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Latest AMED
- SEC Form 15-12G filed by Amedisys Inc
- Twilio Set to Join S&P MidCap 400
- SEC Form S-8 POS filed by Amedisys Inc
- SEC Form S-8 POS filed by Amedisys Inc
- SEC Form S-8 POS filed by Amedisys Inc
- SEC Form S-8 POS filed by Amedisys Inc
- SEC Form S-8 POS filed by Amedisys Inc
- SEC Form S-8 POS filed by Amedisys Inc
- SEC Form S-8 POS filed by Amedisys Inc
- SEC Form S-8 POS filed by Amedisys Inc
Latest TOI
- Director Hively Brad sold $1,946,310 worth of shares (298,853 units at $6.51), decreasing direct ownership by 42% to 411,976 units (SEC Form 4)
- The Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Large owner Chernett Jorey bought $78,480 worth of shares (12,000 units at $6.54), increasing direct ownership by 0.11% to 10,660,858 units (SEC Form 4)
- SEC Form 10-Q filed by The Oncology Institute Inc.
- The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Oncology Institute Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- The Oncology Institute Rebrands as Starling Oncology
- Director Kaushal Mohit was granted 33,133 shares, increasing direct ownership by 19% to 205,716 units (SEC Form 4)
- Director Mcgeorge Anne was granted 41,165 shares, increasing direct ownership by 14% to 332,535 units (SEC Form 4)
- Director Pacala Mark L was granted 30,120 shares, increasing direct ownership by 12% to 286,881 units (SEC Form 4)